Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023		28,237,000
Beginning balance at Dec. 31, 2023	$ 778,641	$ 0	$ 1,047,830	$ 638	$ (269,827)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		260,000
Issuance of common stock upon exercise of stock options	15,969		15,969
Vesting of restricted stock units, net of shares withheld for taxes (in shares)		39,000
Vesting of restricted stock units, net of shares withheld for taxes	(4,181)		(4,181)
Shares of restricted stock awards surrendered for taxes (in shares)		(8,000)
Shares of restricted stock awards surrendered for taxes	(1,205)		(1,205)
Stock-based compensation	10,023		10,023
Unrealized gain (loss) on investments	(875)			(875)
Foreign currency translation	(62)			(62)
Net income	932				932
Ending balance (in shares) at Mar. 31, 2024		28,528,000
Ending balance at Mar. 31, 2024	799,242	$ 0	1,068,436	(299)	(268,895)
Beginning balance (in shares) at Dec. 31, 2023		28,237,000
Beginning balance at Dec. 31, 2023	$ 778,641	$ 0	1,047,830	638	(269,827)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	489,152
Unrealized gain (loss) on investments	$ 713
Net income	43,680
Ending balance (in shares) at Sep. 30, 2024		28,757,000
Ending balance at Sep. 30, 2024	885,846	$ 0	1,110,481	1,512	(226,147)
Beginning balance (in shares) at Mar. 31, 2024		28,528,000
Beginning balance at Mar. 31, 2024	799,242	$ 0	1,068,436	(299)	(268,895)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		181,000
Issuance of common stock upon exercise of stock options	10,637		10,637
Stock-based compensation	13,781		13,781
Unrealized gain (loss) on investments	(252)			(252)
Foreign currency translation	(83)			(83)
Net income	15,568				15,568
Ending balance (in shares) at Jun. 30, 2024		28,709,000
Ending balance at Jun. 30, 2024	838,893	$ 0	1,092,854	(634)	(253,327)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		48,000
Issuance of common stock upon exercise of stock options	3,365		3,365
Stock-based compensation	14,262		14,262
Unrealized gain (loss) on investments	1,840			1,840
Foreign currency translation	306			306
Net income	27,180				27,180
Ending balance (in shares) at Sep. 30, 2024		28,757,000
Ending balance at Sep. 30, 2024	885,846	$ 0	1,110,481	1,512	(226,147)
Beginning balance (in shares) at Dec. 31, 2024		28,794,000
Beginning balance at Dec. 31, 2024	946,380	$ 0	1,127,238	(190)	(180,668)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		17,000
Issuance of common stock upon exercise of stock options	1,462		1,462
Vesting of restricted stock units, net of shares withheld for taxes (in shares)		98,000
Vesting of restricted stock units, net of shares withheld for taxes	(12,116)		(12,116)
Shares of restricted stock awards surrendered for taxes (in shares)		(10,000)
Shares of restricted stock awards surrendered for taxes	(1,812)		(1,812)
Stock-based compensation	14,447		14,447
Unrealized gain (loss) on investments	344			344
Foreign currency translation	236			236
Net income	35,733				35,733
Ending balance (in shares) at Mar. 31, 2025		28,899,000
Ending balance at Mar. 31, 2025	984,674	$ 0	1,129,219	390	(144,935)
Beginning balance (in shares) at Dec. 31, 2024		28,794,000
Beginning balance at Dec. 31, 2024	$ 946,380	$ 0	1,127,238	(190)	(180,668)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	102,468
Unrealized gain (loss) on investments	$ 843
Net income	153,431
Ending balance (in shares) at Sep. 30, 2025		28,984,000
Ending balance at Sep. 30, 2025	1,137,876	$ 0	1,164,013	1,100	(27,237)
Beginning balance (in shares) at Mar. 31, 2025		28,899,000
Beginning balance at Mar. 31, 2025	984,674	$ 0	1,129,219	390	(144,935)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		28,000
Issuance of common stock upon exercise of stock options	1,796		1,796
Stock-based compensation	15,077		15,077
Unrealized gain (loss) on investments	(158)			(158)
Foreign currency translation	925			925
Net income	38,333				38,333
Ending balance (in shares) at Jun. 30, 2025		28,927,000
Ending balance at Jun. 30, 2025	1,040,647	$ 0	1,146,092	1,157	(106,602)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		57,000
Issuance of common stock upon exercise of stock options	3,713		3,713
Stock-based compensation	14,208		14,208
Unrealized gain (loss) on investments	657			657
Foreign currency translation	(714)			(714)
Net income	79,365				79,365
Ending balance (in shares) at Sep. 30, 2025		28,984,000
Ending balance at Sep. 30, 2025	$ 1,137,876	$ 0	$ 1,164,013	$ 1,100	$ (27,237)

Krystal Biotech, Inc. 10-Q